Novocure Executive and Leadership Team

Francis Leonard, the Chief Executive Officer at Novocure, directs the company's overarching strategy and global operations. Leonard guides Novocure's mission to extend survival for patients with aggressive cancers, focusing on the commercialization and development of Tumor Treating Fields (TTFields) therapy. This leadership involves overseeing clinical trial expansion across multiple cancer types, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Francis Leonard ensures alignment with regulatory bodies and market access initiatives in key regions such as the U.S., Europe, Japan, and Israel. The CEO's role encompasses driving financial performance, fostering strategic partnerships, and maintaining Novocure's position as a leader in innovative oncology treatments. Leonard's executive decisions shape the company's research pipeline and market penetration strategies, directly impacting patient access to TTFields therapy.

Mukund Paravasthu, the Chief Operating Officer at Novocure, manages the company's day-to-day operational execution and global infrastructure. Paravasthu oversees the scaling of Novocure's commercial operations, ensuring efficient delivery of its Tumor Treating Fields (TTFields) therapy to patients worldwide. This involves optimizing manufacturing processes, supply chain logistics, and customer support functions across Novocure's presence in Switzerland, the U.S., Germany, Japan, and Israel. The Chief Operating Officer drives operational excellence initiatives, focusing on process improvements that enhance efficiency and reduce costs. Mukund Paravasthu collaborates with other executive leaders to translate strategic goals into actionable operational plans, ensuring the company can meet growing market demand. This role is critical for maintaining the integrity and accessibility of Novocure's innovative cancer treatment.

Matthew Thaeder, the Chief of Staff To President at Novocure, provides strategic support and operational coordination for the President's office. Thaeder facilitates the execution of key initiatives and ensures seamless communication across executive departments and global operations. This role involves managing critical projects, preparing executive briefings, and driving cross-functional alignment to advance Novocure's strategic objectives. Matthew Thaeder supports the President in overseeing the company's global expansion and commercialization efforts for Tumor Treating Fields (TTFields) therapy. The Chief of Staff To President plays a pivotal part in streamlining decision-making processes and enhancing organizational efficiency. Thaeder's responsibilities include driving special projects that support the company's mission to extend survival in aggressive cancers.

Yoram Palti, the Founder & Chief Technology Officer at Novocure, spearheads the technological innovation and development of the company's core therapy. Palti leads the research and development efforts focused on advancing Tumor Treating Fields (TTFields) technology, exploring its application across a broad spectrum of aggressive cancers. This involves directing scientific research, product engineering, and intellectual property strategy to maintain Novocure's technological edge. Yoram Palti works closely with clinical teams to integrate technological advancements with patient treatment protocols, ensuring the efficacy and safety of TTFields. The Chief Technology Officer's vision guides the exploration of new technological frontiers in oncology, driving the discovery of novel applications and improvements to the existing therapy. Palti's foundational role ensures Novocure remains at the forefront of cancer treatment innovation.

Uri Weinberg, the Chief Innovation Officer & Chief Medical Officer at Novocure, directs the company's medical strategy and drives innovation in oncology treatment. Weinberg oversees the clinical development programs for Tumor Treating Fields (TTFields) therapy, guiding research into new cancer indications and therapeutic applications. This leadership involves managing clinical trials, ensuring adherence to medical best practices, and translating scientific insights into clinical advancements. Uri Weinberg collaborates with research teams to foster innovation, exploring novel approaches to cancer care and enhancing the efficacy of TTFields. The Chief Innovation Officer & Chief Medical Officer ensures that Novocure's medical and scientific endeavors align with the company's mission to extend patient survival. Weinberg's dual role is crucial for advancing the clinical adoption and therapeutic potential of TTFields globally.